Seeking Alpha

Somaxon Pharma (SOMX) up another 12% premarket, adding to a 27% gain Monday, on speculation...

Somaxon Pharma (SOMX) up another 12% premarket, adding to a 27% gain Monday, on speculation ahead of a scheduled FDA action date for its insomnia treatment Silenor. "We continue to view Silenor as having a competitive product profile in a crowded insomnia marketplace, but we remain wary of Somaxon's recent cash balance of $5M and our view of its reliance on Silenor's approval in order to sustain operations, given lack of pipeline depth," S&P said.
Comments (1)
  • herbert hoover
    , contributor
    Comments (2005) | Send Message
     
    So they have one drug and it's up for an approval (or not) by the FDA. Double or nothing! Red or black? Who says that the stock market is nothing but a giant (crooked?) casino?
    1 Dec 2009, 08:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|